Home > Boards > US Listed > Medical - Equipment > Itamar Medical Ltd. (ITMR)

SVB Leerink starts Itamar Medical at OP; PT $30

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
midastouch017 Member Profile
 
Followed By 128
Posts 26,174
Boards Moderated 4
Alias Born 02/07/04
160x600 placeholder
Post-effective Amendment to Registration Statement (pos Am) Edgar (US Regulatory) - 12/16/2021 4:11:41 PM
Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse) Edgar (US Regulatory) - 12/16/2021 8:42:15 AM
Itamar Medical EPS beats by $0.23, beats on revenue Seeking Alpha - 11/18/2021 6:24:10 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/18/2021 6:04:28 AM
Itamar Medical Reports Third Quarter 2021 Financial Results GlobeNewswire Inc. - 11/18/2021 6:00:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/16/2021 4:06:47 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 10/14/2021 5:21:24 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 10/4/2021 6:05:02 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 9/13/2021 5:28:31 PM
ATER, AXTI and OIIM among mid-day movers Seeking Alpha - 9/13/2021 1:25:44 PM
Amended Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k/a) Edgar (US Regulatory) - 8/12/2021 8:25:03 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 8/12/2021 6:36:47 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 8/12/2021 6:31:21 AM
Itamar Medical Appoints Marga Ortigas-Wedekind to its Board of Directors GlobeNewswire Inc. - 8/12/2021 6:00:00 AM
Itamar Medical Reports Second Quarter 2021 Financial Results GlobeNewswire Inc. - 8/10/2021 6:00:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 7/28/2021 6:08:19 AM
Itamar Medical to Report Second Quarter Financial Results and Host Conference Call on Tuesday, August 10, 2021 GlobeNewswire Inc. - 7/28/2021 6:00:00 AM
Teleflex and Itamar sell off “too draconian”: Piper Sandler Seeking Alpha - 7/16/2021 4:57:40 PM
Itamar Medical to Present at the Ladenburg Thalmann Annual Healthcare Conference on Wednesday, July 14, 2021 GlobeNewswire Inc. - 6/30/2021 6:00:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 6/17/2021 11:07:41 AM
Itamar Medical Launches Enhancements to WatchPAT™ Product Line at SLEEP 2021 GlobeNewswire Inc. - 6/7/2021 6:00:00 AM
Itamar Medical Appoints Brad Fluegel to its Board of Directors GlobeNewswire Inc. - 5/24/2021 6:00:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 5/20/2021 6:09:20 AM
Itamar Medical EPADS beats by $0.01, beats on revenue Seeking Alpha - 5/19/2021 6:03:06 AM
Itamar Medical Reports First Quarter 2021 Results GlobeNewswire Inc. - 5/19/2021 6:00:00 AM
midastouch017   Saturday, 06/13/20 07:11:04 AM
Re: None
Post # of 12 
SVB Leerink starts Itamar Medical at OP; PT $30

Stephen KilmerJune 12, 2020

SVB Leerink launched coverage of Itamar Medical (NASDAQ, TASE:ITMP) with an “outperform” rating and $30 price target. The stock closed at $16.01 on June 11.

“We see Itamar as an underappreciated high growth/gross margin (30%, 75%-plus)
small-cap company with a unique home sleep apnea test (HSAT) solution (WatchPAT) poised to continue taking share in an expanding (and double digit growth) HSAT segment,” writes analyst Richard Newitter.

He figures the HSAT segment is on track to at least double within the next three years to $200-million, and “even still would be underpenetrated relative to a potential $3.2-billion sleep apnea testing total addressable market,” according to a company estimate.

Mr. Newitter said that as Itamar extends its distribution capabilities and grows awareness for WatchPAT’s value proposition within this growing HSAT category, “we project the company can triple its sales over the next three years driving an above-average 30% compound annual growth rate in the process.”

Mr. Newitter said the company’s nexgen WatchPAT One product, launched in the U.S. in November 2019, represents a “first-of-kind fully disposable HSAT, with our positive MEDACorp feedback suggesting it will be a significant differentiator for Itamar both during and post-COVID-19.”

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences